Tamsulosin hydrochloride - Generic Drug Details

What are the generic drug sources for tamsulosin hydrochloride and what is the scope of patent protection?

Tamsulosin hydrochloride is the generic ingredient in two branded drugs marketed by Sanofi, Alkem Labs Ltd, Ascent Pharms Inc, Aurobindo Pharma Ltd, Chartwell Rx, Impax Labs, Macleods Pharms Ltd, Ph Health, Pharmobedient, Rising, Sandoz, Sciegen Pharms, Sun Pharm Inds Ltd, Synthon Bv, Teva Pharms, and Zydus Pharms Usa Inc, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for tamsulosin hydrochloride. Thirty-six suppliers are listed for this compound.

Summary for tamsulosin hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	16
NDAs:	16
Drug Master File Entries:	32
Finished Product Suppliers / Packagers:	36
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	236
Patent Applications:	3,944
What excipients (inactive ingredients) are in tamsulosin hydrochloride?	tamsulosin hydrochloride excipients list
DailyMed Link:	tamsulosin hydrochloride at DailyMed

Recent Clinical Trials for tamsulosin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Peking University First Hospital	PHASE4
Taiyuan Central Hospital of Shanxi Medical University	PHASE4
Peking University First Hospital Miyun Hospital	PHASE4

See all tamsulosin hydrochloride clinical trials

Pharmacology for tamsulosin hydrochloride

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for tamsulosin hydrochloride

G04CA	Alpha-adrenoreceptor antagonists
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for TAMSULOSIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FLOMAX	Capsules	tamsulosin hydrochloride	0.4 mg	020579	1	2004-12-20

US Patents and Regulatory Information for tamsulosin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	202010-001	Jan 4, 2013		DISCN	No	No
Sanofi	FLOMAX	tamsulosin hydrochloride	CAPSULE;ORAL	020579-001	Apr 15, 1997		DISCN	Yes	No
Sun Pharm Inds Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	090931-001	Jul 15, 2010		DISCN	No	No
Pharmobedient	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	090408-001	Apr 27, 2010		DISCN	No	No
Rising	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	219767-001	May 1, 2025	AB	RX	No	No
Aurobindo Pharma Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	202433-001	Apr 30, 2013	AB	RX	No	No
Sciegen Pharms	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	078938-001	Apr 27, 2010	AB	RX	No	No

Expired US Patents for tamsulosin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi	FLOMAX	tamsulosin hydrochloride	CAPSULE;ORAL	020579-001	Apr 15, 1997	4,703,063*PED
Sanofi	FLOMAX	tamsulosin hydrochloride	CAPSULE;ORAL	020579-001	Apr 15, 1997	4,731,478
Sanofi	FLOMAX	tamsulosin hydrochloride	CAPSULE;ORAL	020579-001	Apr 15, 1997	4,868,216
Sanofi	FLOMAX	tamsulosin hydrochloride	CAPSULE;ORAL	020579-001	Apr 15, 1997	4,772,475

Tamsulosin hydrochloride Market Analysis and Financial Projection

Last updated: February 8, 2026

Market Dynamics and Financial Trajectory for Tamsulosin Hydrochloride

Market Overview

Tamsulosin hydrochloride, marketed primarily under the brand name Flomax, is a selective alpha-1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH). Its mechanism involves relaxation of smooth muscle in the prostate and bladder neck, easing urinary flow.

The global BPH therapeutics market was valued at approximately USD 4.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030, driven by an aging population and increased early diagnosis. Tamsulosin accounts for an estimated 35-40% market share of BPH pharmacological treatments, making it one of the leading therapies globally.

Key Market Drivers

1. Aging Population: By 2030, individuals aged 65 and older are expected to reach 1 billion worldwide, constituting a significant patient base for BPH treatment.
2. Product Patent Expirations: Several branded formulations face patent cliffs. Tamsulosin’s patent expired in 2011 in the U.S. but remains under exclusivity in certain markets due to extended formulations and combination therapies, maintaining high sales in select regions.
3. Growing Preference for Pharmacotherapy: The shift from surgical interventions to oral medications enhances market stability for Tamsulosin, especially in developed countries.
4. Emerging Markets: Rapid urbanization and increasing healthcare access in China, India, and Brazil expand the potential patient pool.

Competitive Landscape

• Generic Tamsulosin: Proliferates after patent expiry; accounts for a significant share of sales due to lower cost.
• Combination Therapies: Tamsulosin is increasingly combined with other medications like Dutasteride, expanding treatment options.
• New Molecular Entities: Limited direct competition exists; however, alternative therapies like tadalafil and minimally invasive procedures are evolving.

Price Dynamics

Global pricing varies:

Region	Brand-Name Price (USD per month)	Generic Price (USD per month)
US	$60 - $80	$20 - $40
Europe	€50 - €70	€15 - €30
Asia	$10 - $20	$5 - $15

In the US, branded formulations retain higher margins, but sales are declining post-patent expiration. Generics have eroded price points, affecting overall revenue.

Regulatory Landscape

Tamsulosin is approved in over 80 countries. Regulatory exclusivity policies vary:

• US: Patent expired in 2011; FDA approval granted in 1997.
• Europe: Market exclusivity lasting 10 years; generics introduced post-expiry.
• Emerging Markets: Regulatory pathways are less stringent, enabling quick entry of generics.

Financial Trajectory

Historical Revenue Data:

Year	Sales (USD Millions)	Market Share	Notes
2018	1,250	25%	Dominant in BPH pharmacotherapy
2020	1,100	22%	Post patent expiry, decline begins
2022	950	20%	Generic competition intensifies

Forecast to 2030:

• Revenue Growth: CAGR of approximately 2-3% from 2023-2030.
• Market Penetration: Continued erosion of brand revenue offset by growth in emerging markets.
• Cost of Goods Sold (COGS): Declines with generic proliferation.
• Research & Development (R&D): Minimal investment due to mature product lifecycle.

Key Risks and Opportunities

• Risks: Patent cliffs, competitive commoditization, and potential regulatory restrictions on combination therapies.

• Opportunities: Expansion into combination formulations, novel delivery systems, or new indications like lower urinary tract symptoms (LUTS) management could stabilize revenues.

---

Key Takeaways

• Tamsulosin hydrochloride dominates the BPH pharmacotherapy market, but revenues face pressure from patent expirations and generics.
• Global market growth driven by aging populations and increasing diagnosis rates.
• Price competition is intense in generics, with regional variations.
• The product’s financial outlook suggests slow, steady decline in mature markets, balanced by growth prospects in emerging regions.
• Opportunities exist in formulation innovation and combination therapies but require R&D investment.

---

FAQs

1. How has patent expiration impacted Tamsulosin sales?
Patent expiration in the U.S. in 2011 led to increased generic competition, reducing branded sales and increasing the availability of low-cost alternatives.

2. What regions offer the highest growth potential?
Emerging markets like China, India, and Brazil exhibit the highest growth potential due to increasing healthcare access and aging demographics.

3. Are there significant competitors to Tamsulosin?
Yes. Other alpha-1 blockers (e.g., Terazosin, Alfuzosin) and non-pharmacological treatments are competitors, alongside evolving therapies like tadalafil.

4. What strategies could sustain revenue streams?
Developing combination drugs, exploring new indications, and improving delivery methods provide potential avenues for revenue stabilization.

5. What regulatory challenges exist for Tamsulosin?
Patent challenges, approval of generics, and evolving regulation of combination therapies could affect market dynamics.

---

References

1. MarketWatch. "Benign Prostatic Hyperplasia Treatment Market." 2022.
2. Grand View Research. "Alpha-Blockers Market Analysis." 2022.
3. FDA. "Drug Approvals and Patent Data." 2023.
4. IMS Health. "Global Pharmacology Trends." 2022.
5. European Medicines Agency. "Regulatory Overview of BPH Drugs." 2022.